“…As examples, Byrne et al used a registry to examine the natural history of Pompe disease 68 ; three registries pursued quality improvement (stroke care, cardiac catheterization and management of childhood diabetes [69][70][71] ); disease subgroup characterization was facilitated for pituitary and lung tumors, 72,73 post-market device monitoring for cardiovascular stents, 74,75 as well as monitoring of treatment outcomes and safety follow up for cardiac transplant patients receiving everolimus, general cardiac care, biological agents for arthritis, giant intracranial aneurysms, and TPA for ischemic stroke. [76][77][78][79][80] Other registries aimed to serve innovative roles:…”